Discussion in 'Health News and Research unrelated to ME/CFS' started by Andy, Apr 22, 2018.
Annoyingly only 20 test subjects but interesting ...not sure whether there is a tangible link to how this translates into better health rather than a general association with improvements to stiffening of arteries in old age. Be interesting to know whether there is a difference taking the horrendously expensive MitoQ once per day vs a larger dose of the supposedly inferior (but cheaper) ubiquinol several times a day?
The Montoya study though discounts this as an effective treatment I seem to recall....(my recall is pretty poor so forgive me if this is misremembered) but I seem to remember that this used weak methodology?
I wish we could have something more definitive like 200 test subjects double blinded with a detailed objective set of measures over 3-6 months.
According to the article,
Something I meant to add to my original post.
It also makes me wonder whether this is a good or a bad thing for us. From memory, there is some evidence for endothelial dysfunction in ME patients, if this improved the range of function (dilation and contraction) then great, if it simply helps to dilate blood vessels then not so great.
Sherpa, on the other forum, posted about his benefits from MitoQ.
According to the study done by D Newton and colleagues, as summarised by ME research,
I don't know much about this, but it sounds as if MitoQ's effects - increased flow mediated dilation, reduced arterial stiffness, reduced oxidative stress - could be potentially helpful for us.
(The Newton paper is currently available via http://sci-hub.hk, doi.org/10.1016/j.ijcard.2011.10.030)
Separate names with a comma.